Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,883
Total Claims
$1.9M
Drug Cost
380
Beneficiaries
$4,882
Cost/Patient
Risk Score Breakdown 31/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+6%
Opioid rate vs peers
2.7% vs 2.6% avg
+357%
Cost per patient vs peers
$4,882 vs $1,068 avg
+99%
Brand preference vs peers
18.0% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
2.7%
Opioid Rate
270
Opioid Claims
$3,121
Opioid Cost
8.5%
Long-Acting Rate
Brand vs Generic
Brand: 1,753 claims · $1.7M
Generic: 8,012 claims · $143K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Bictegrav/Emtricit/Tenofov Ala | 54 | $219K |
| Semaglutide | 112 | $189K |
| Abacavir/Dolutegravir/Lamivudi | 28 | $104K |
| Emtricitabine/Tenofov Alafenam | 38 | $89K |
| Dolutegravir Sodium | 38 | $87K |
| Emtricitab/Rilpiviri/Tenof Ala | 24 | $81K |
| Apixaban | 91 | $80K |
| Darunavir/Cobicistat | 31 | $77K |
| Dulaglutide | 69 | $77K |
| Empagliflozin | 56 | $53K |
| Fluticasone/Umeclidin/Vilanter | 71 | $50K |
| Sitagliptin Phosphate | 32 | $50K |
| Elviteg/Cob/Emtri/Tenof Alafen | 12 | $49K |
| Insulin Regular, Human | 40 | $45K |
| Umeclidinium Bromide | 70 | $34K |
Prescribing Profile
Patient Profile
66
Avg Age
66%
Female
1.77
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About